Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report.

Revista espanola de enfermedades digestivas - 1 Oct 2010

Barreiro-de Acosta M, Ouburg S, Morré S A, Crusius J B A, Lorenzo A, Potel J, Salvador-Peña A, Domínguez-Muñoz J E

Abstract excerpt

INTRODUCTION: Adalimumab is a recombinant fully-human monoclonal immunoglobulin (IgG1) antibody utilized in the treatment of Crohn's disease. Unfortunately no clinical or genetic markers exist to predict response to anti-tumor necrosis factor-alpha (TNF) therapy. The aim of this study was to evaluate the association between selected genes involved in cytokine regulation and response to adalimumab treatment in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Anti-Inflammatory Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal

Share to Antibodies, Monoclonal, Humanized

Share to Crohn Disease

Share to Lipopolysaccharide Receptors

Share to Nod2 Signaling Adaptor Protein

Share to Toll-Like Receptor 4

Source

Identifiers

PMID: 21039068
DOI: 10.4321/s1130-01082010001000005

Genes

TNF
NOD2
TLR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report.PMID 21039068Read ↗

Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients.Semantic proximity Read ↗

Mutations in the NOD2 gene are associated with a specific phenotype and lower anti‐tumor necrosis factor trough levels in Crohn's diseaseSemantic proximity Read ↗

Tolllike receptor 4 (TLR4) polymorphisms in Tunisian patients with Crohn's disease: genotype-phenotype correlation.Semantic proximity Read ↗

NOD2 polymorphism predicts response to treatment in Crohn's disease--first steps to a personalized therapy.Semantic proximity Read ↗

Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease.Semantic proximity Read ↗

Lack of association of the 3'-UTR polymorphism in the NFKBIA gene with Crohn's disease in an Israeli cohort.Semantic proximity Read ↗

Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease.Semantic proximity Read ↗

Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy.Semantic proximity Read ↗

A Prospective Pharmacogenomic Study of Crohn's Disease Patients during Routine Therapy with Anti-TNF-α Drug Adalimumab: Contribution of ATG5, NFKB1, and CRP Genes to Pharmacodynamic Variability.Semantic proximity Read ↗

Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases.Semantic proximity Read ↗

NOD2/CARD15 does not influence response to infliximab in Crohn's disease.Semantic proximity Read ↗

Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.